The First Limb Transplants with Cyclosporine
Cyclosporine was first described in 1976 as a fungal metabolite and found to have remarkable immunosuppressive properties both experimentally and clinically. It was several years later that at the University of California, Irvine, College of Medicine, Drs. Kirby Black (Research Director for the Plastic Surgery Division within the Department of Surgery) and Charles W. Hewitt (Director of Research for the Division of Urology within the Department of Surgery) found themselves next door to one another, each directing the research efforts of their respective divisions. Dr. Black's interests at the time were in developing models of ischemia reperfusion injury and flap studies in the field of Plastic Surgery and Dr. Hewitt's primary interests were in studying transplant rejection and mechanisms of tolerance induction, as the Division of Urology was the division that was primarily responsible for kidney transplantation at the University of California, Irvine.
KeywordsComposite Tissue Skin Graft Survival Limb Transplant Immunosuppressive Compound Miracle Drug
Unable to display preview. Download preview PDF.
- 1.J. F. Borel, C. Feurer, H. U. Gubler, et al., Biological effects of cyclosporine A: A new anti-lymphocytic agent, Agents Actions 468 (1976).Google Scholar
- 3.C. W. Hewitt, K. S. Black, L. A. Fraser, et al., Cyclosporin A (CyA) is superior to prior donor-specific blood (DSB) transfusion for the extensive prolongation of rat limb allograft survival, Transplant Proc 15, 514–517 (1983).Google Scholar
- 12.B. D. Kahan, Cosmas and Damian revisited, Transplant Proc 4(Suppl 1), 2211 (1983).Google Scholar